Health & Fitness
Health and Fitness
Health and Fitness
Thu, December 18, 2008
Wed, December 17, 2008
Adolor Corporation to Host Conference Call to Provide R&D Update
EXTON, Pa.--([ BUSINESS WIRE ])--Adolor Corporation (Nasdaq:ADLR) today announced that it will hold a conference call at 8:30 a.m. ET on Thursday, December 18, 2008 to provide an R&D program update, including its delta agonist and opioid bowel dysfunction (OBD) programs.
To participate in the audio portion and have the opportunity to pose questions, dial (866) 394-4329 for domestic callers, or (706) 902-1952 for international callers, and enter Conference ID #77986885. Investors also can listen to the call live by logging on to the Company's website at [ www.adolor.com ] and clicking on "Investor Insights," then "Webcast." Please click on the link and follow the prompts for registration and access.
A replay of the call will be available beginning approximately two hours after the event until 11:00 p.m. ET, December 25, 2008. To listen to a replay of the conference call, dial (800) 642-1687 (domestic) or (706) 645-9291 (international) and enter Conference ID #77986855 or listen via Adolor's website. The replay will be available for one week.
About Adolor Corporation
Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.
Adolor's first approved product in the United States is Entereg® (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. Entereg is available for short-term use in hospitals registered under the Entereg Access Support and Education (E.A.S.E.) Program. In collaboration with GlaxoSmithKline, the company launched Entereg in mid-2008. For more information, visit [ www.adolor.com ].
